Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
JangoPet is a veterinary biotechnology company dedicated to extending the healthy lifespan of companion animals through advanced regenerative medicine. A subsidiary of JangoBio, the company focuses on restoring youthful hormone levels in aging dogs and cats using proprietary cell-based therapies. Their approach involves the transplantation of hormone-producing cells to reverse age-related decline and treat conditions such as cognitive dysfunction and frailty. By addressing the underlying hormonal imbalances associated with aging, JangoPet aims to improve the quality of life for pets and their owners. The company leverages research on the hypothalamic-pituitary-gonadal axis to develop long-term solutions for pet longevity.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on JangoPet.